pd 1 antagonist Search Results


90
Nektar Inc pd-1 antagonist
Pd 1 Antagonist, supplied by Nektar Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/pd+1+antagonist/us12358978-101-16-57
Average 90 stars, based on 1 article reviews
pd-1 antagonist - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Array BioPharma pembrolizumab (antagonist pd-1 mab) antibody
Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.
Pembrolizumab (Antagonist Pd 1 Mab) Antibody, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/pembrolizumab++antagonist+pd+1+mab++antibody/pmc05609554-83-6-20
Average 90 stars, based on 1 article reviews
pembrolizumab (antagonist pd-1 mab) antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Polpharma antagonistic pd1 antibody
Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.
Antagonistic Pd1 Antibody, supplied by Polpharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/antagonistic+pd1+antibody/pm32905903-340-14-9
Average 90 stars, based on 1 article reviews
antagonistic pd1 antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co 5 mg/kg of a monoclonal anti-mouse pd-1 antagonist antibody (mudx400) [78afs]
Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.
5 Mg/Kg Of A Monoclonal Anti Mouse Pd 1 Antagonist Antibody (Mudx400) [78afs], supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/monoclonal+anti+mouse+pd1+antagon/us10899840-574-96-102
Average 90 stars, based on 1 article reviews
5 mg/kg of a monoclonal anti-mouse pd-1 antagonist antibody (mudx400) [78afs] - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Incyte corporation nivolumab (pd-1 antagonist mab)
Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.
Nivolumab (Pd 1 Antagonist Mab), supplied by Incyte corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/nivolumab++pd+1+antagonist+mab++antibody/pmc05609554-71-6-21
Average 90 stars, based on 1 article reviews
nivolumab (pd-1 antagonist mab) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genentech inc compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.
Compositions For Treating Cancer Using Pd 1 Axis Binding Antagonists And Mek Inhibitors, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/compositions+for+treating+cancer+using+pd+1+axis+binding+antagonists+and+mek+inhibitors/pm27054314-180-109-117
Average 90 stars, based on 1 article reviews
compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co embrolizumab (keytruda
Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.
Embrolizumab (Keytruda, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/pembrolizumab+anti/pm39271090-42-3-7
Average 90 stars, based on 1 article reviews
embrolizumab (keytruda - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genentech inc methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.
Methods Of Treating Cancer Using Pd 1 Axis Binding Antagonists And Mek Inhibitors, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/methods+of+treating+cancer+using+pd+1+axis+binding+antagonists+and+mek+inhibitors+antibody/pm29227196-133-79-82
Average 90 stars, based on 1 article reviews
methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Heumann Pharma pd-1 antagonist
Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.
Pd 1 Antagonist, supplied by Heumann Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+1+antagonist/pd+1+antagonist/pm38976079-209-15-2
Average 90 stars, based on 1 article reviews
pd-1 antagonist - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier


Image Search Results


Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.

Journal: Frontiers in Immunology

Article Title: Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

doi: 10.3389/fimmu.2017.01024

Figure Lengend Snippet: Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.

Article Snippet: NCT02880371 Phase I/II (recruiting, 2016) , • Pembrolizumab (antagonist PD-1 mAb) • ARRY-382 (CSF1R) , Metastatic tumors including MM , Array BioPharma , A Study of ARRY-382 in combination with pembrolizumab, a programmed cell death receptor 1 (PD-1) antibody, for the treatment of patients with advanced solid tumors , • Part A: escalating doses of ARRY-382 with pembrolizumab 2 mg/kg. • Part B: ARRY-382 at MTD with pembrolizumab 2 mg/kg. • Part C: ARRY-382 at MTD with 200 mg pembrolizumab.

Techniques: Clinical Proteomics, Blocking Assay

Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.

Journal: Frontiers in Immunology

Article Title: Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

doi: 10.3389/fimmu.2017.01024

Figure Lengend Snippet: Clinical trials combining immune checkpoint blockade with immunostimulatory strategies.

Article Snippet: NCT02327078 Phase I/II (recruiting, 2014) , • Nivolumab (PD-1 antagonist mab) • epacadostat (IDO-1 inhibitor) , Metastatic tumors including MM , Incyte Corporation , A Phase 1/2 study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) , • Phase 1: nivolumab IV 3 mg/kg/2 weeks plus epacadostat 25 mg BID as starting dose, followed by dose escalations. • Phase 2: nivolumab 240 mg 2 weeks plus epacadostat MTD.

Techniques: Activity Assay, Injection, Modification, Expressing, Biomarker Assay, Ex Vivo, In Situ

Other combinations in clinical trials with immunomodulatory monoclonal antibodies.

Journal: Frontiers in Immunology

Article Title: Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

doi: 10.3389/fimmu.2017.01024

Figure Lengend Snippet: Other combinations in clinical trials with immunomodulatory monoclonal antibodies.

Article Snippet: NCT02327078 Phase I/II (recruiting, 2014) , • Nivolumab (PD-1 antagonist mab) • epacadostat (IDO-1 inhibitor) , Metastatic tumors including MM , Incyte Corporation , A Phase 1/2 study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) , • Phase 1: nivolumab IV 3 mg/kg/2 weeks plus epacadostat 25 mg BID as starting dose, followed by dose escalations. • Phase 2: nivolumab 240 mg 2 weeks plus epacadostat MTD.

Techniques: Expressing, Injection

Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.

Journal: Frontiers in Immunology

Article Title: Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

doi: 10.3389/fimmu.2017.01024

Figure Lengend Snippet: Clinical trials combining immune checkpoint blockade with targeting of immunosuppressive molecules.

Article Snippet: NCT02327078 Phase I/II (recruiting, 2014) , • Nivolumab (PD-1 antagonist mab) • epacadostat (IDO-1 inhibitor) , Metastatic tumors including MM , Incyte Corporation , A Phase 1/2 study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) , • Phase 1: nivolumab IV 3 mg/kg/2 weeks plus epacadostat 25 mg BID as starting dose, followed by dose escalations. • Phase 2: nivolumab 240 mg 2 weeks plus epacadostat MTD.

Techniques: Blocking Assay